Author: Dr Michiel van der Heijden (on-camera comments) – Courtesy of ESMO.org Advertisement Checkmate 901, a study focusing on first-line treatment for metastatic or irresectable urothelial cancer patients, aimed to improve existing chemotherapy approaches. Traditionally, chemotherapy, primarily cisplatin or gemcitabine, has been the standard for such cases. With the recent introduction of immunotherapy, there has … Continue reading CheckMate 901: Nivolumab/Chemo Sets New Standard for Metastatic Urothelial Carcinoma